CY1120114T1 - Υδατικα ποσιμα διαλυματα απο στεροειδεις ορμονες και υδροξυπροπυλο-βητα-κυκλοδεξτρινη με βελτιστοποιημενη βιοδιαθεσιμοτητα - Google Patents

Υδατικα ποσιμα διαλυματα απο στεροειδεις ορμονες και υδροξυπροπυλο-βητα-κυκλοδεξτρινη με βελτιστοποιημενη βιοδιαθεσιμοτητα

Info

Publication number
CY1120114T1
CY1120114T1 CY20181100366T CY181100366T CY1120114T1 CY 1120114 T1 CY1120114 T1 CY 1120114T1 CY 20181100366 T CY20181100366 T CY 20181100366T CY 181100366 T CY181100366 T CY 181100366T CY 1120114 T1 CY1120114 T1 CY 1120114T1
Authority
CY
Cyprus
Prior art keywords
oral administration
hydroxypypylon
cyclodexine
aquatic
biology
Prior art date
Application number
CY20181100366T
Other languages
English (en)
Inventor
Alberto Bernareggi
Nadia Puppini
Alessandro Nencioni
Original Assignee
Altergon S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altergon S.A. filed Critical Altergon S.A.
Publication of CY1120114T1 publication Critical patent/CY1120114T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά στην παρασκευή και τη θεραπευτική χρήση υδατικών διαλυμάτων Προγεστερόνης ή Τεστοστερόνης, συμπλοκοποιημένων με υδροξυπροπυλο-β-κυκλοδεξτρίνης (ΗΡβCD) που είναι κατάλληλα για χορήγηση από το στόμα. Τα διαλύματα χαρακτηρίζονται από μια συγκεκριμένη γραμμομοριακή αναλογία ανάμεσα στη ΗΡβCD και τις ορμόνες προκειμένου να εξασφαλιστούν υψηλά επίπεδα ορμόνης στο πλάσμα, μετά από χορήγηση από το στόμα, χάρη στη βελτιστοποίηση της διαλυτότητας, της διαπερατότητας, της μεταβολικής σταθερότητας και εν τέλει της βιοδιαθεσιμότητάς τους. Η μορφοποίηση αντικείμενο του παρόντος διπλώματος ευρεσιτεχνίας είναι δυνατό να πετύχει αποτελεσματικές συγκεντρώσεις στο πλάσμα μετά από χορήγηση από το στόμα χαμηλότερων δόσεων ορμόνης αναφορικά με πόσιμες μορφοποιήσεις που διανέμονται προς το παρόν στην αγορά (π.χ. Prometrium, Andriol) προς όφελος της μεγαλύτερης ασφάλειας και τη συμβατότητας των ασθενών.
CY20181100366T 2012-11-28 2018-04-03 Υδατικα ποσιμα διαλυματα απο στεροειδεις ορμονες και υδροξυπροπυλο-βητα-κυκλοδεξτρινη με βελτιστοποιημενη βιοδιαθεσιμοτητα CY1120114T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002027A ITMI20122027A1 (it) 2012-11-28 2012-11-28 Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata
PCT/EP2013/003538 WO2014082724A1 (en) 2012-11-28 2013-11-22 Aqueous oral solutions of steroid hormones and hydroxypropyl-beta-cyclodextrin with optimised bioavailability

Publications (1)

Publication Number Publication Date
CY1120114T1 true CY1120114T1 (el) 2018-12-12

Family

ID=47633163

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100366T CY1120114T1 (el) 2012-11-28 2018-04-03 Υδατικα ποσιμα διαλυματα απο στεροειδεις ορμονες και υδροξυπροπυλο-βητα-κυκλοδεξτρινη με βελτιστοποιημενη βιοδιαθεσιμοτητα

Country Status (14)

Country Link
US (2) US10646586B2 (el)
EP (1) EP2925369B1 (el)
CN (1) CN104853780B (el)
CA (1) CA2891632C (el)
CY (1) CY1120114T1 (el)
DK (1) DK2925369T3 (el)
ES (1) ES2664596T3 (el)
HU (1) HUE037290T2 (el)
IT (1) ITMI20122027A1 (el)
NO (1) NO2925369T3 (el)
PL (1) PL2925369T3 (el)
PT (1) PT2925369T (el)
RU (1) RU2662314C2 (el)
WO (1) WO2014082724A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata
CN106902357B (zh) 2015-12-21 2021-08-03 广州市香雪制药股份有限公司 药物组合物及其应用、药物包合物、静脉制剂及制备方法
CN106902358B (zh) 2015-12-21 2020-07-10 广州市香雪制药股份有限公司 口服制剂及其制备方法
ITUB20161027A1 (it) * 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5895783A (en) * 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
RU2316328C1 (ru) * 2006-05-30 2008-02-10 Государственное образовательное учреждение дополнительного профессионального образования Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию Способ коррекции частичного возрастного андрогенного дефицита (padam) и препаративная форма тестостерона или его фармакологически приемлемых производных для его осуществления
ITMI20071971A1 (it) 2007-10-10 2009-04-11 Altergon Sa Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata

Also Published As

Publication number Publication date
CA2891632A1 (en) 2014-06-05
US10842883B2 (en) 2020-11-24
PT2925369T (pt) 2018-04-09
PL2925369T3 (pl) 2018-08-31
US20150297752A1 (en) 2015-10-22
ITMI20122027A1 (it) 2014-05-29
HUE037290T2 (hu) 2018-08-28
US20200230258A1 (en) 2020-07-23
CA2891632C (en) 2020-09-15
CN104853780B (zh) 2019-11-05
EP2925369A1 (en) 2015-10-07
RU2015117684A (ru) 2017-01-10
CN104853780A (zh) 2015-08-19
WO2014082724A1 (en) 2014-06-05
ES2664596T3 (es) 2018-04-20
EP2925369B1 (en) 2018-01-03
NO2925369T3 (el) 2018-06-02
DK2925369T3 (en) 2018-04-16
US10646586B2 (en) 2020-05-12
RU2662314C2 (ru) 2018-07-25

Similar Documents

Publication Publication Date Title
CY1120114T1 (el) Υδατικα ποσιμα διαλυματα απο στεροειδεις ορμονες και υδροξυπροπυλο-βητα-κυκλοδεξτρινη με βελτιστοποιημενη βιοδιαθεσιμοτητα
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
AR097791A1 (es) Formulaciones de anticuerpos anti-pdl1
MX2015006998A (es) Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
PH12016500720A1 (en) Stable formulation of insulin glulisine
NZ631833A (en) Emulsion formulations
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
CY1116142T1 (el) Εισπνεομενο φαρμακο που περιλαμβανει τιοτροπιο
MX2016005142A (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
CY1124635T1 (el) Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
BR112015023481A8 (pt) projeto de perfil de liberação de fármaco de controle via composição de lipossomo em ambos os compartimentos aquosos e não-aquosos
CY1118570T1 (el) Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου
CL2017001417A1 (es) Conjugados de ácido benzoico, derivados de ácido benzoico y de ácidos carboxílicos heteroarilos de oximorfona, prodrogas, métodos y preparación y uso de los mismos